Vivos Therapeutics, Inc. (VVOS)
- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $0.14
- As of
Kresmion compiles this page from VVOS's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Vivos Therapeutics, Inc. (VVOS): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-10-15.
See the full VVOS dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for VVOS on one page. Preview it with sample data, then open it live with a free account.
Preview the VVOS dossierActive signals for VVOS
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 21.4%, EPS $-0.31 vs $-0.3944 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 17.6% - EPS $-0.58 vs $-0.493 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 40.1% - EPS $-0.55 vs $-0.3927 estimate
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 5.8% - EPS $-0.49 vs $-0.5202 estimate
- mediumEARNINGS_MISS
Missed consensus by 17.6% - EPS $-0.58 vs $-0.493 estimate
FREE, NO ACCOUNT
Every signal on VVOS, as it fires
You are seeing 5 of 6 signals recorded on VVOS since 2026-05-31.
The five above landed across 3 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter. Historical quarters remain available above.
Recent SEC filings, VVOS
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
VVOS against its peers
VVOS's operating margin of -114.1% ranks in the 65th percentile of 12 Medical Devices sub-industry peers, fiscal periods ending between 2025-09-30 and 2026-06-30.
| Metric | VVOS | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 17.4M USD | 2.7M USD | 97 | 15 |
| Revenue YoY | n/a | -14.4% | n/a | 5 |
| Gross margin | 60.4% | 40.5% | 71 | 11 |
| Operating margin | -114.1% | -231.0% | 65 | 12 |
| Net margin | -121.4% | -294.9% | 61 | 13 |
| Return on equity | n/a | -166.4% | n/a | 15 |
| 1 year | -95.5% | -90.8% | 18 | 13 |
Peers (19): INBS, USAQ, NVNO, STME, AIDX, AMIX, NXL, WOK, VNRX, ADGM, TANAF, ICCM, IVF, BJDX, CODX, ADMT, BMRA, AEMD, TNON. Left out: SONX (period gap), TRIB (period gap), KLYG (no annual filing), CYDX (no annual filing), PMEDF (period gap), NMTC (no annual filing). Fiscal periods ending between 2025-09-30 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (VVOS: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow VVOS on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to VVOS for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.